Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...

American private investment firm Bain Capital is on the verge of acquiring a significant stake in Manappuram Finance, one of Kerala’s leading gold loan providers, in a deal valued at ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

BAIN CAPITAL SPECIALTY FINANCEDL-NOTES 2025 (25/30) (US05684BAD91) - All master data, key figures and real-time diagram.

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...